Imagen de Portada

Perioperative Targeted Immunotherapy Combined With Transarterial Chemoembolization Improves Survival in Borderline Resectable Hepatocellular Carcinoma

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Jianwei Liu, Ming Tang, Jianbing Xuan, Tianle Tang, Yameng Zhong, Junyong Ma, Liu Liu, Zhishi Yang, Wenxin Wei, Han Wang, Kui Wang, Feng Shen, Yong Xia
Formato:	Artículo Open Access
Publicado:	Wiley 2026
Materias:	International Journal of Cancer
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Long‐Term Survival and Prognostic Factors of Stereotactic Body Radiotherapy Following Transarterial Chemoembolization for Hepatocellular Carcinoma
por: Hoang Dong Duc, et al.
Publicado: (2025)

Transarterial Chemoembolization With or Without Systemic Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Comparative Study
por: Chengxiang Guo, et al.
Publicado: (2025)

Mineralized Supramolecular Microspheres with Immunoregulating Functions for Transarterial Chemoembolization Immunotherapy of Hepatocellular Carcinoma
por: Miya Zhang, et al.
Publicado: (2025)

Recent Advances in Embolic Agents for Transarterial Chemoembolization of Hepatocellular Carcinoma
por: Yiming Liu, et al.
Publicado: (2025)

Survival and Perioperative Outcomes After Addition of Immunotherapy to Neoadjuvant Chemoradiotherapy for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma
por: Canjun Li, et al.
Publicado: (2025)

Survival Benefit and Safety of Anatomic Resection in Cirrhotic Hepatocellular Carcinoma: Propensity‐Matched Analysis of 1699 Patients
por: Ao Du, et al.
Publicado: (2026)

Adjuvant Transarterial Chemoembolization After Truly Curative Resection Does Not Improve Survival of Patients With Hepatocellular Carcinoma at High Risk of Recurrence: A Target Trial Emulation Study
por: Jia‐Yong Su, et al.
Publicado: (2025)

Emerging Trends in Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: A Focus on Liver Transplant Candidates
por: Dongdong Yu, et al.
Publicado: (2025)

MR Radiomics Combined With Radiologic Features to Predict Recurrence Location in Nonviable Hepatocellular Carcinoma After Transarterial Chemoembolization
por: Shuhang Zhang, et al.
Publicado: (2026)

Gut Microbiota and Hepatocellular Carcinoma: Metabolic Products and Immunotherapy Modulation
por: Kunmin Xiao, et al.
Publicado: (2025)

Durvalumab Monotherapy in Complex Advanced Hepatocellular Carcinoma: A Real‐World Study of Patients Ineligible for Combination Immunotherapy
por: Chihiro Miwa, et al.
Publicado: (2025)

SNAPIN Facilitates Progression of Hepatocellular Carcinoma by Hindering Ferroptosis Through KEAP1 Degradation Promotion
por: Xuan Liu, et al.
Publicado: (2025)

The Impact of Adjuvant Radiotherapy Combined With Targeted or Immunotherapy on the Heart in Breast Cancer
por: Dongmin Liu, et al.
Publicado: (2026)

Exploratory Investigation Into Perioperative Treatment Strategies for Potentially Resectable Stage III – N2 Driver Gene–Negative Non–Small Cell Lung Cancer in the Immunotherapy Era
por: Jiarui Zhao, et al.
Publicado: (2026)

Transarterial Chemoembolization for Patients With Hepatocellular Carcinoma Using Miriplatin Without the Need for Hydration
por: Koji Fujita, et al.
Publicado: (2025)

Clinical Benefit and Safety of Combined Immunotherapy and Targeted Therapy in Prostate Cancer
por: Zeyu Han, et al.
Publicado: (2026)

Optimal Neoadjuvant Approach for Resectable Esophageal Cancer in the Era of Immunotherapy
por: Guo Lin, et al.
Publicado: (2026)

A Novel Amino Acid‐Related Gene Signature Predicts Overall Survival in Patients With Hepatocellular Carcinoma
por: Shuyi Wang, et al.
Publicado: (2024)

MRI ‐Based Score to Predict Retreatment Response for Viable Hepatocellular Carcinomas After Transarterial Chemoembolization
por: Weilang Wang, et al.
Publicado: (2025)

Correlation Between Treatment‐Related Adverse Events and Efficacy of Camrelizumab in Combination With Apatinib in Patients With Unresectable Hepatocellular Carcinoma
por: Ting Zhang, et al.
Publicado: (2025)

Transarterial Infusion Chemotherapy and Embolization for Patients With Unresectable Advanced Cancer of Stomach or Gastroesophageal Junction: A Retrospective Study
por: Lingqiang Min, et al.
Publicado: (2024)

Bi‐Regional Machine Learning Radiomics Based on CT Noninvasively Predicts LOX Expression Level and Overall Survival in Hepatocellular Carcinoma
por: Kexin Gao, et al.
Publicado: (2025)

Prognostic Value of a Novel Model for Hepatocellular Carcinoma Patients Undergoing Transarterial Chemoembolization
por: Cailing Ye, et al.
Publicado: (2025)

A Contrast‐Enhanced Ultrasound Cine‐Based Deep Learning Model for Predicting the Response of Advanced Hepatocellular Carcinoma to Hepatic Arterial Infusion Chemotherapy Combined With Systemic Therapies
por: Xu Han, et al.
Publicado: (2025)

T Cell Heterogeneity Shaped by Alternative Splicing Predicts Prognosis in Hepatocellular Carcinoma
por: Xiaohui Peng, et al.
Publicado: (2026)

Prediction Model for Familial Aggregated HBV ‐Associated Hepatocellular Carcinoma Based on Serum Biomarkers
por: Linmei Zhong, et al.
Publicado: (2025)

Consolidation Chemotherapy Provided Survival Benefit for Esophageal Squamous Cell Carcinoma Patients Who Underwent Concurrent Chemoradiotherapy Lower Than 60 Gy
por: Hualei Zhang, et al.
Publicado: (2025)

Methyltransferase‐Like 14 Promotes the Angiogenesis of Hepatocellular Carcinoma via Targeting Vascular Endothelial Growth Factor A
por: Xinmiao Xiong, et al.
Publicado: (2026)

Kupffer Phase Radiomics Signature in Sonazoid Contrast‐Enhanced Ultrasound Predicts Immunohistochemistry Marker Expression in Hepatocellular Carcinoma
por: Chen Li, et al.
Publicado: (2025)

Preoperative Serum Glycan Levels Reflect Progression of Patients With Hepatocellular Carcinoma
por: Sheng‐Sheng Liu, et al.
Publicado: (2024)

MicroRNA Let‐7b‐5p Targets IGF1R to Inhibit the Progression of Hepatocellular Carcinoma Through the AKT/mTOR Pathway
por: Jiaojiao Liang, et al.
Publicado: (2025)

Transcriptome Concordance Between Borderline Tumors and Endometrioid Carcinoma: An Integrative Genomic Analysis
por: Mio Takahashi, et al.
Publicado: (2025)

Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma
por: Atsushi Naganuma, et al.
Publicado: (2025)

Machine Learning‐Based Model for Predicting Recurrence‐Free Survival After Interventional Therapy in Malnourished Hepatocellular Carcinoma Patients
por: Ningning Lu, et al.
Publicado: (2025)

Alpelisib and Immunotherapy: A Promising Combination for Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Riham Suleiman, et al.
Publicado: (2024)

Differences in Tumor‐Infiltrating Lymphocyte Counts in the Peritumoral Area in Patients Undergoing Hepatic Resection After Lenvatinib and Atezolizumab Plus Bevacizumab Therapy for Hepatocellular Carcinoma
por: Katsuya Toshida, et al.
Publicado: (2025)

The Role of RANBP3L in Pan‐Cancer With Its Significance in Hepatocellular Carcinoma
por: Beini Cen, et al.
Publicado: (2025)

Predictive Value of Radiographic Tumor Burden Score in Hepatocellular Carcinoma Within Milan Criteria After Microwave Ablation: Implications for Long‐Term Outcomes and Treatment Planning
por: Xiaolin Liu, et al.
Publicado: (2025)

Oncological Outcomes Following Different TACE ‐Based Conversion Therapies for Intermediate‐Advanced Hepatocellular Carcinoma
por: Hongwei Xu, et al.
Publicado: (2026)

MASTL Promotes Hepatocellular Carcinoma Progression and Paclitaxel Resistance Through Mitotic Catastrophe
por: Ke Wang, et al.
Publicado: (2025)